Cingulate (CING) Return on Capital Employed (2022 - 2026)
Cingulate's (CING) quarterly Return on Capital Employed came in at 865.59% in Q4 2025, down 69646.0% YoY from N/an in Q4 2024, and down 324.91% on a QoQ basis from 203.71% in Q1 2025.
Cingulate (CING) Return on Capital Employed (2022 - 2026) Analysis & Trends
Cingulate (CING) has 4 years of Return on Capital Employed data on file, last reported at 865.59% in Q4 2025.
- Quarterly Return on Capital Employed fell 69646.0% year-over-year to 865.59% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 865.59% (down 69646.0% YoY) and the FY2025 annual result came in at 428.2%, down 5622.0% from the prior year.
- Return on Capital Employed slipped to 865.59% in Q4 2025, from 203.71% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 11132.54% in Q3 2023 to a low of 972.42% in Q1 2024.
- A 4-year average of 539.05% and a median of 197.61% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed soared 1132405 bps — and 2024, when it tumbled 1134037 bps.
- Tracing CING's Return on Capital Employed over 4 years: stood at 274.4% in 2022, then jumped by 250 bps to 410.45% in 2023, then tumbled by 141 bps to 169.13% in 2024, then tumbled by 412 bps to 865.59% in 2025.
- The last three Return on Capital Employed figures came in at 865.59% (Q4 2025), 203.71% (Q1 2025), and 169.13% (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Cingulate | 70.68 Mn | 70.68 Mn | - | -140.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -140.21% |
| Dec 31, 2025 | -865.59% |
| Mar 31, 2025 | -203.71% |
| Dec 31, 2024 | -169.13% |
| Sep 30, 2024 | -207.83% |
| Jun 30, 2024 | -572.33% |
| Mar 31, 2024 | -972.42% |
| Dec 31, 2023 | 410.45% |
| Sep 30, 2023 | 11,132.54% |
| Jun 30, 2023 | 388.69% |
| Mar 31, 2023 | -622.45% |
| Dec 31, 2022 | -274.40% |
| Sep 30, 2022 | -191.51% |
| Jun 30, 2022 | -177.59% |
| Mar 31, 2022 | -128.01% |